Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

The P100 ESWT device provided symptom relief for type IIIB CP/CPPS over 4 weeks, particularly in the pain and urinary domains. Low-intensity extracorporeal shock wave therapy (ESWT) using a novel ...

A recently published article from Turkey 1 discusses perceived limitations of the International Prostate Symptom Score (IPSS) in evaluating male lower urinary tract symptoms (LUTS) and whether the ...

New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men. MENLO PARK, Calif., Nov. 20, 2025 /PRNewswire/ -- MyOme, ...

Transurethral resection of the prostate (TURP) remains the gold standard in treating complications from benign prostate hyperplasia (BPH), even amid advances in minimally invasive techniques. However, ...

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...